Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SeaStar Medical Holding Corp (ICU)

SeaStar Medical Q2 revenue rises to $0.6 million; net loss widens to $3.7 million

Mixed Impact 3 of 5 earnings Written later

SeaStar Medical reported second quarter 2026 results, with net revenue of about $0.6 million, up from about $0.3 million a year earlier, driven by growth in QUELIMMUNE sales. The net loss widened to about $3.7 million, or $0.91 per share, from about $2.0 million, or $1.77 per share, as research and development and general and administrative expenses rose, and cash fell to $7.0 million at June 30, 2026 from $12.0 million at December 31, 2025.

Key points

  • Net revenue for the quarter was about $0.6 million versus about $0.3 million in the second quarter of 2025; the company added 3 new QUELIMMUNE customers, bringing the total to 20.
  • Research and development expenses rose to $2.5 million from $1.0 million, and general and administrative expenses rose to about $1.8 million from $1.0 million.
  • Net loss was about $3.7 million, or $0.91 per share, on about 4.1 million weighted-average shares, compared with about $2.0 million, or $1.77 per share, on about 1.1 million shares a year earlier.
  • Cash was $7.0 million at June 30, 2026, down from $12.0 million at December 31, 2025.

The filing

CompanySeaStar Medical Holding Corp (ICU)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:10 PM ET
Accession number0001437749-26-027314

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.